Human embryonic stem cell (hESC)-derived oligodendrocyte progenitor cells (OPCs) are being studied for cell replacement therapies, including the treatment of acute spinal cord injury. Current methods of differentiating OPCs from hESCs require complex, animal-derived biological extracellular matrices (ECMs). Defined, low-cost, robust, and scalable culture methods will need to be developed for the widespread deployment and commercialization of hESC-derived cell therapies. Here we describe a defined culture system that uses a vitronectin-derived synthetic peptide acrylate surface (VN-PAS; commercially available as Corning® Synthemax® surface) in combination with a defined culture medium for hESC growth and differentiation to OPCs. We show that synthetic VN-PAS supports OPC attachment and differentiation, and that hESCs grown on VN-PAS are able to differentiate into OPCs on VN-PAS. Compared to OPCs derived from hESCs grown on ECM of animal origin, higher levels of NG2, a chondroitin sulfate proteoglycan expressed by OPCs, were observed in OPCs differentiated from H1 hESCs grown on VN-PAS, while the expression levels of Nestin and PDGFRα were comparable. In summary, this study demonstrates that synthetic VN-PAS can replace complex, animal-origin ECM to support OPC differentiation from hESCs.
Get full access to this article
View all access options for this article.
References
1.
FehlingsMG, VawdaR. 2011. Cellular treatments for spinal cord injury: the time is right for clinical trials. Neurotherapeutics, 8:704–720.
2.
RowlandJW, HawrylukGW, KwonB, FehlingsMG. 2008. Current status of acute spinal cord injury pathophysiology and emerging therapies: promise on the horizon. Neurosurg Focus, 25:E2.
3.
TalacR, FriedmanJA, MooreMJ, LuL, JabbariE, WindebankAJ, CurrierBL, YaszemskiMJ. 2004. Animal models of spinal cord injury for evaluation of tissue engineering treatment strategies. Biomaterials, 25:1505–1510.
4.
WatsonRA, YeungTM. 2011. What is the potential of oligodendrocyte progenitor cells to successfully treat human spinal cord injury?BMC Neurol, 11:113.
5.
RonaghiM, ErcegS, Moreno-ManzanoV, StojkovicM. 2010. Challenges of stem cell therapy for spinal cord injury: human embryonic stem cells, endogenous neural stem cells, or induced pluripotent stem cells?Stem Cells, 28:93–99.
6.
WrightKT, El MasriW, OsmanA, ChowdhuryJ, JohnsonWE. 2011. Concise review: Bone marrow for the treatment of spinal cord injury: mechanisms and clinical applications. Stem Cells, 29:169–178.
7.
NistorGI, TotoiuMO, HaqueN, CarpenterMK, KeirsteadHS. 2005. Human embryonic stem cells differentiate into oligodendrocytes in high purity and myelinate after spinal cord transplantation. Glia, 49:385–396.
8.
SundbergM, SkottmanH, SuuronenR, NarkilahtiS. 2010. Production and isolation of NG2+oligodendrocyte precursors from human embryonic stem cells in defined serum-free medium. Stem Cell Res, 5:91–103.
9.
PouyaA, SatarianL, KianiS, JavanM, BaharvandH. 2011. Human induced pluripotent stem cells differentiation into oligodendrocyte progenitors and transplantation in a rat model of optic chiasm demyelination. PLoS One, 6:e27925.
10.
KeirsteadHS, NistorG, BernalG, TotoiuM, CloutierF, SharpK, StewardO. 2005. Human embryonic stem cell-derived oligodendrocyte progenitor cell transplants remyelinate and restore locomotion after spinal cord injury. J Neurosci, 25:4694–4705.
11.
KerrCL, LetzenBS, HillCM, AgrawalG, ThakorNV, SterneckertJL, GearhartJD, AllAH. 2010. Efficient differentiation of human embryonic stem cells into oligodendrocyte progenitors for application in a rat contusion model of spinal cord injury. Int J Neurosci, 120:305–313.
WirthE3rd, LebkowskiJS, LebacqzK. 2011. Response to Frederic Bretzner et al. Target populations for first-in-human embryonic stem cell research in spinal cord injury. Cell Stem Cell, 8:476–478.
14.
Geron Corporation: Press Release Nov 14. (2011). Geron to Focus on its Novel Cancer Programs. http://ir.geron.com/phoenix.zhtml?.c=67323&p=irol-newsArticle&ID=1635764&highlight. 2012 Nov 06.
15.
HuJ, DengL, WangX, XuXM. 2009. Effects of extracellular matrix molecules on the growth properties of oligodendrocyte progenitor cells in vitro. J Neurosci Res, 87:2854–2862.
16.
HuBY, DuZW, ZhangSC. 2009. Differentiation of human oligodendrocytes from pluripotent stem cells. Nat Protoc, 4:1614–1622.
AmitM, SharikiC, MarguletsV, Itskovitz-EldorJ. 2004. Feeder layer- and serum-free culture of human embryonic stem cells. Biol Reprod, 70:837–845.
27.
LiY, PowellS, BrunetteE, LebkowskiJ, MandalamR. 2005. Expansion of human embryonic stem cells in defined serum-free medium devoid of animal-derived products. Biotechnol Bioeng, 91:688–698.
28.
RowlandTJ, MillerLM, BlaschkeAJ, DossEL, BonhamAJ, HikitaST, JohnsonLV, CleggDO. 2010. Roles of integrins in human induced pluripotent stem cell growth on Matrigel and vitronectin. Stem Cells Dev, 19:1231–1240.
29.
ChenG, GulbransonDR, HouZ, BolinJM, RuottiV, ProbascoMD, Smuga-OttoK, HowdenSE, DiolNRet al.2011. Chemically defined conditions for human iPSC derivation and culture. Nat Methods, 8:424–429.
30.
MiyazakiT, FutakiS, HasegawaK, KawasakiM, SanzenN, HayashiM, KawaseE, SekiguchiK, NakatsujiN, SuemoriH. 2008. Recombinant human laminin isoforms can support the undifferentiated growth of human embryonic stem cells. Biochem Biophys Res Commun, 375:27–32.
31.
ProwseAB, DoranMR, Cooper-WhiteJJ, ChongF, MunroTP, FitzpatrickJ, ChungTL, HaylockDN, GrayPP, WolvetangEJ. 2010. Long term culture of human embryonic stem cells on recombinant vitronectin in ascorbate free media. Biomaterials, 31:8281–8288.
32.
RodinS, DomogatskayaA, StromS, HanssonEM, ChienKR, InzunzaJ, HovattaO, TryggvasonK. 2010. Long-term self-renewal of human pluripotent stem cells on human recombinant laminin-511. Nat Biotechnol, 28:611–615.
33.
BraamSR, ZeinstraL, LitjensS, Ward-van OostwaardD, van den BrinkS, van LaakeL, LebrinF, KatsP, HochstenbachRet al.2008. Recombinant vitronectin is a functionally defined substrate that supports human embryonic stem cell self-renewal via alphavbeta5 integrin. Stem Cells, 26:2257–2265.
34.
DerdaR, MusahS, OrnerBP, KlimJR, LiL, KiesslingLL. 2010. High-throughput discovery of synthetic surfaces that support proliferation of pluripotent cells. J Am Chem Soc, 132:1289–1295.
35.
IrwinEF, GuptaR, DashtiDC, HealyKE. 2011. Engineered polymer-media interfaces for the long-term self-renewal of human embryonic stem cells. Biomaterials, 32:6912–6919.
36.
KlimJR, LiL, WrightonPJ, PiekarczykMS, KiesslingLL. 2010. A defined glycosaminoglycan-binding substratum for human pluripotent stem cells. Nat Methods, 7:989–994.
37.
Villa-DiazLG, NandivadaH, DingJ, Nogueira-de-SouzaNC, KrebsbachPH, O'SheaKS, LahannJ, SmithGD. 2010. Synthetic polymer coatings for long-term growth of human embryonic stem cells. Nat Biotechnol, 28:581–583.
38.
MelkoumianZ, WeberJL, WeberDM, FadeevAG, ZhouY, Dolley-SonnevilleP, YangJ, QiuL, PriestCAet al.2010. Synthetic peptide-acrylate surfaces for long-term self-renewal and cardiomyocyte differentiation of human embryonic stem cells. Nat Biotechnol, 28:606–610.
39.
HoffmanLM, CarpenterMK. 2005. Characterization and culture of human embryonic stem cells. Nat Biotechnol, 23:699–708.
40.
AllegrucciC, YoungLE. 2007. Differences between human embryonic stem cell lines. Hum Reprod Update, 13:103–120.
41.
ZhangYW, DenhamJ, ThiesRS. 2006. Oligodendrocyte progenitor cells derived from human embryonic stem cells express neurotrophic factors. Stem Cells Dev, 15:943–952.
42.
WeberJL, Dolley-SonnevilleP, WeberDM, FadeevAG, ZhouY, YangJ, PriestCA, BrandenbergerR, MelkoumianZ. 2010. Corning® Synthemax™ Surface: a tool for feeder-free, xeno-free culture of human embryonic stem cells. Nat Methods, 7:an6–an7.
43.
OgawaS, TokumotoY, MiyakeJ, NagamuneT. 2011. Induction of oligodendrocyte differentiation from adult human fibroblast-derived induced pluripotent stem cells. In Vitro Cell Dev Biol Anim, 47:464–469.
44.
BlaschukKL, FrostEE, ffrench-ConstantC. 2000. The regulation of proliferation and differentiation in oligodendrocyte progenitor cells by alphaV integrins. Development, 127:1961–1969.
45.
BrafmanDA, ChangCW, FernandezA, WillertK, VargheseS, ChienS. 2010. Long-term human pluripotent stem cell self-renewal on synthetic polymer surfaces. Biomaterials, 31:9135–9144.
46.
MahlstedtMM, AndersonD, SharpJS, McGilvrayR, MunozMD, ButteryLD, AlexanderMR, RoseFR, DenningC. 2010. Maintenance of pluripotency in human embryonic stem cells cultured on a synthetic substrate in conditioned medium. Biotechnol Bioeng, 105:130–140.
47.
LiuY, WangX, KaufmanDS, ShenW. 2011. A synthetic substrate to support early mesodermal differentiation of human embryonic stem cells. Biomaterials, 32:8058–8066.
48.
SerraM, BritoC, CorreiaC, AlvesPM. 2012. Process engineering of human pluripotent stem cells for clinical application. Trends Biotechnol, 30:350–359.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
